GlassScriptPhysician profile
Renee S Mcentire
NPI 1043240757
$3,876.13
in general payments reported to CMS, 2019-2025
18 companies · $460 in 2025
The $460 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $454 · 2021: $193 · 2022: $231 · 2023: $177 · 2024: $1,834 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482 · Travel and Lodging: $989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.83 |
| Travel and Lodging | $988.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,485.16 | 2021-2025 | Total30, Rocklatan, Precision7 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $499.76 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $458.84 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $336.42 | 2022-2025 | Miebo, Infuse, Xiidra |
| Tarsus Pharmaceuticals, INC. | $249.63 | 2024-2025 | Xdemvy |
| Allergan, INC. | $197.31 | 2019-2022 | |
| Oyster Point Pharma, INC. | $156.56 | 2022-2025 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $102.02 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $86.73 | 2021-2025 | |
| Kala Pharmaceuticals, INC. | $62.39 | 2019-2022 | |
| Glaukos Corporation | $48.25 | 2025 | |
| Abbvie INC. | $41.24 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $36.26 | 2025 | Eylea Hd, Eylea |
| Dompe US, INC. | $30.76 | 2024 | Oxervate |
| Coopervision INC. | $29.04 | 2023-2025 | Myday Contact Lens |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $20.65 | 2023 | Vabysmo |
| Astellas Pharma US INC | $18.22 | 2023 | |
| Biotissue Holdings INC. | $16.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Mcentire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.